Sunshine Biopharma, Inc. (NASDAQ: SBFM) is engaged as a pharmaceutical company, which is focused on the discovery, research, development, and commercialization of antiviral and cancer drugs. The company is also working on developing new treatments to help combat the ongoing COVID-19 pandemic. Shares of the oncology pharmaceutical company are skyrocketing 144% through early trading on Tuesday, April 5, 2022. Over the past three months, Sunshine Biopharma has seen average daily volume of 1.5 million shares. However, volume of 86.9 million shares or dollar volume of around $446.67 million, has already exchanged hands through early trading.
Shares of Sunshine Biopharma are soaring after the company announced that its recently-developed mRNA molecules have shown to be effective in treating multi-drug resistant cancer cells in culture. During the cytotoxicity tests, the company utilized multidrug resistant breast cancer cells, ovarian adenocarcinoma cells and pancreatic cancer cells to test with the mRNA molecules. The molecules had little to no cytotoxic effect and were able to destroy the cancer cell’s growth.
The mRNA molecules are easily and readily adaptable to be delivered to patients using mRNA vaccine technology. Sunshine Biopharma says they plan to file a patent application to secure its intellectual property related to the results.
Dr. Steve Slilaty, CEO of Sunshine Biopharma: “We are delighted by these findings in connection with our ongoing mRNA-as-therapeutic-agents research. The potential use of mRNA to treat cancer opens the door to many possibilities for patients including convenience, reduced toxicity and enhanced efficacy.”
Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/
